When we live our Patients First core value, we maintain an intense focus on improving patients’ lives. Across our Commercial Team, our #BlueCrew works tirelessly to educate healthcare professionals and support patient access to our innovation. Read how Chris Sloan and Cammy Hill incorporate this value into their work on our Market Access and Sales teams:
Blueprint Medicines
生物技术研究
Cambridge，Massachusetts 51,399 位关注者
Striving to improve and extend patients' lives
关于我们
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
- 网站
-
https://www.blueprintmedicines.com
Blueprint Medicines的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2011
- 领域
- targeted therapy、systemic mastocytosis、breast cancer、allergy/inflammatory、hematology/oncology、solid tumors、drug design和mast cell biology
地点
Blueprint Medicines员工
动态
-
We’re proud to be named a Top 100 Healthcare Technology Company for 2024 by The Healthcare Technology Report, following our Chief Commercial Officer Philina Lee's recognition as a Top 25 Biotech Executive earlier this year. We've worked to hone our research platform that enables agile and cutting-edge drug discovery, empowering us to tackle complex medical challenges. Thank you to our #BlueCrew for your commitment to improving patients' lives every day.?
-
-
Recently, the #BlueCrew had a great time hosting Cancer Support Community's annual fundraiser. We're committed to the local Boston community of patients and families, and we're proud to support this organization that delivers resources, financial counseling, and well-being assistance to people impacted by cancer.
-
-
At Blueprint Medicines, we are committed to encouraging new and diverse talent to enter the life sciences industry. Last week, Christopher Murray attended the American Chemical Society's second LEADS Conference, which connects distinguished scientists with aspiring scientific professionals looking to start their careers in chemical sciences. Below, read a few highlights from Chris from the conference and insights about a scientific career:
-
-
This month, members of our #BlueCrew attended annual conferences for Women of Color in Pharma (WOCIP) and Young Black Pharma, two groups that work to elevate the voices of people of color in the life sciences industry. We're committed to investing in development opportunities for people from marginalized or underrepresented communities, ensuring diverse talent across the #BlueCrew is celebrated and everyone has access to professional development opportunities.
-
-
Last month, our CEO Kate Haviland attended the National Organization for Rare Disorders Breakthrough Summit with over 900 members of the rare disease community. Kate joined a panel with other biotech CEOs and senior leaders to discuss how to support access to rare disease treatments. We strive to improve outcomes for people around the world by delivering innovative therapies that meet their clinical needs and positively impact their lives. #NORDSummit Read more from Kate below:
-
-
On November 14, we’re hosting an educational scientific seminar with renowned expert Paul O'Byrne to discuss how we plan to further develop our mast cell disease portfolio. Our industry-leading expertise in mast cell biology combined with our innovative research engine enables an agile approach, as we seek to address larger patient populations with high medical needs. Learn more: https://bit.ly/3ClSueJ
-
As we work to advance care for systemic mastocytosis (SM), we seek to understand the diverse needs and experiences of patients to improve awareness of SM and its unique impact on each individual. Through initiatives like our #ColorsOfSM program, in partnership with Twist Out Cancer, we aim to foster empathy and greater support for people living with SM.
-
Earlier this month, we hosted mentees from HBPA Harvard Medical School Black Postdoc Association at our Cambridge office to engage in practical career-building sessions such as mock interviews, aiming to help students translate their postdoc skills into an industry career. At Blueprint Medicines, we believe that having perspectives from a range of backgrounds allows us to meaningfully deliver for the patients we serve. We're committed to supporting and developing talent from historically marginalized backgrounds.
-
We’re proud to have supported the first of three Patient and Family Seminars for indolent systemic mastocytosis (ISM), hosted by Medscape/WebMD in partnership with The Mast Cell Disease Society, Inc. (TMS) and the American Initiative in Mast Cell Diseases. These educational seminars offer a unique space for patients and their families to connect with each other and learn directly from leading medical experts, fostering a deeper understanding of ISM and helping them confidently navigate their journey. Read more from Jessica Fraser, Executive Director at TMS, following the first seminar.
-